Journal of Human Reproductive Sciences

: 2020  |  Volume : 13  |  Issue : 4  |  Page : 249-

Editorial Commentary

Padma Rekha Jirge 
 Sushrut Assisted Conception Clinic, Shreyas Hospital, Kolhapur, Maharashtra, India

Correspondence Address:
Dr. Padma Rekha Jirge
Sushrut Assisted Conception Clinic, Shreyas Hospital, Kolhapur, Maharashtra

How to cite this article:
Jirge PR. Editorial Commentary.J Hum Reprod Sci 2020;13:249-249

How to cite this URL:
Jirge PR. Editorial Commentary. J Hum Reprod Sci [serial online] 2020 [cited 2021 Oct 19 ];13:249-249
Available from:

Full Text

October–December issue of the Journal of Human Reproductive Sciences is an acknowledgment of untiring efforts of reproductive medicine specialists for the progress of science in the face of challenges posed by COVID-19 pandemic. It gives me immense pleasure to write my first editorial for the Journal, which has been guided and steered efficiently by Dr. Kamini Rao and Dr. Madhuri Patil since its inception.

A review by Wiweko and Zakirah provides a perspective for the importance of disruptive innovations and their ever-increasing contributions to the field of assisted reproduction. The review article on anti-Müllerian hormone (AMH) summarizes the current knowledge of the analyte, which has had a great impact on our understanding of ovarian physiology and ovarian health. It is of note that Prof. Richard Fleming has been intricately involved in the development of AMH assay and its clinical utility.

A systematic review by Deswal et al. and a prospective study by Kamrul-Hasan et al. from India and Bangladesh, respectively, address the much-needed issues of prevalence of polycystic ovary syndrome and the metabolic and hormonal disturbances seen in its different phenotypes in this part of the world. I encourage everyone to read the two original articles on the molecular diagnosis of genital tuberculosis in infertile women by Tiwari et al. and Ashwini et al. They attempt to define the place of these modalities in the diagnosis of an elusive condition. Furthermore, these studies identify an important lacuna for any progress in this important area, the lack of a commonly accepted composite gold standard against which the sensitivity of any new test can be compared. A randomized controlled trial by Noor et al. attempts to address the relative contribution of artificial intelligence in follicular monitoring in women undergoing in vitro fertilization (IVF), while the article on integration of an electronic witnessing system in IVF laboratory provides initial data on the safety of its use at the laboratory level.

This issue has three original articles addressing the impact of COVID on the practice of reproductive medicine. While one addresses the emotional impact of the pandemic on infertile individuals, the other two address the safe practice of laparoscopy and assisted reproductive treatment, incorporating national and international guidelines. They provide preliminary objective evidence of safe utilization of these services during the protracted and unpredictable course of this pandemic.

An original study on development of neovagina in a cohort with the distressing Mayer–Rokitansky–Küster–Hauser syndrome and the genes associated with successful formation of neovagina raises an interesting opportunity for the role of genetic engineering in the management of certain Mullerian defects.

The study on thyroxine therapy in hypothyroid infertile women draws our attention to a common and correctable etiology of infertility and the need to address it in the initial stages of management of infertility. The article on Egyptian couples with recurrent pregnancy loss (RPL) suggests that the presence and etiological role of chromosomal aberrations in couples with RPL may be similar across different ethnicities. Two case reports on multiple endocrine neoplasia and Mullerian anomaly highlight the management of these rare but clinically relevant problems.